Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLGAI-004
- Development stage
- Unknown
- Lead developer
- Peptilogics
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Peptides
01
Overview
PLGAI-004 is a synthetic peptide-based therapeutic under development by Peptilogics for the treatment of cancer (neoplasms). It is classified as an antineoplastic agent and represents a new molecular entity. The drug is being developed using Peptilogics' AI-driven platform, Nautilus. As of the latest updates in early 2025, its mechanism of action remains undefined or undisclosed. The compound has not received orphan drug status and is currently in the discovery or early research phase with no clinical trial data reported[1][2][7].
Beyond the preview
Go deeper on PLGAI-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLGAI-004.